Human Kal l ikre in 6 ( hK 6 ) : A New Potent ia l Serum Biomarker for Diagnosis and Prognosis of Ovar ian Carc inoma
暂无分享,去创建一个
D. Katsaros | G. Yousef | A. Scorilas | E. Diamandis | I. Vergote | U. Stenman | M. Massobrio | S. Fracchioli | Alfthan Henrik | A. Soosaipillai | L. Grass | M. V. Gramberen | A. V. D. Zee | H. D. Bruijn
[1] M. Duffy. The role of proteolytic enzymes in cancer invasion and metastasis , 1992, Clinical & Experimental Metastasis.
[2] B. R. Hoffman,et al. Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker , 2002, British Journal of Cancer.
[3] R. Berkowitz,et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. , 2002, JAMA.
[4] D. Katsaros,et al. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. , 2001, Cancer research.
[5] G. Mills,et al. Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. , 2001, Journal of the National Cancer Institute.
[6] R. Berkowitz,et al. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. , 2001, Journal of the National Cancer Institute.
[7] P. Paley. Ovarian cancer screening: are we making any progress? , 2001, Current opinion in oncology.
[8] H. Samaratunga,et al. Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] D. Katsaros,et al. Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] D. Katsaros,et al. Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] M. Ringnér,et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks , 2001, Nature Medicine.
[12] G. Yousef,et al. The new human tissue kallikrein gene family: structure, function, and association to disease. , 2001, Endocrine reviews.
[13] A. Scorilas,et al. Human kallikrein 10: a novel tumor marker for ovarian carcinoma? , 2001, Clinica chimica acta; international journal of clinical chemistry.
[14] D. Katsaros,et al. The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] D. Katsaros,et al. Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer , 2001, British Journal of Cancer.
[16] D. Lockhart,et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[17] M. Barry,et al. Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. , 2001, The New England journal of medicine.
[18] Taylor Murray,et al. Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.
[19] K. Shigemasa,et al. Overexpression of Testisin, a Serine Protease Expressed by Testicular Germ Cells, in Expithelial Ovarian Tumor Cells , 2000, The Journal of the Society for Gynecologic Investigation: JSGI.
[20] G. Yousef,et al. Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. , 2000, Clinical biochemistry.
[21] G. Yousef,et al. Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. , 2000, Clinical biochemistry.
[22] G. Rustin,et al. Role of tumour markers in monitoring epithelial ovarian cancer , 2000, British Journal of Cancer.
[23] Eleftherios P. Diamandis,et al. The New Human Kallikrein Gene Family: Implications in Carcinogenesis , 2000, Trends in Endocrinology & Metabolism.
[24] John Clarke,et al. The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells , 1999, Cancer.
[25] Ian J. Jacobs,et al. SCREENING FOR OVARIAN CANCER : A PILOT RANDOMISED CONTROLLED TRIAL , 1999 .
[26] L. Matrisian,et al. Cancer biology: Extracellular proteinases in malignancy , 1999, Current Biology.
[27] Roger E Bumgarner,et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. , 1999, Gene.
[28] Z. Ye,et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[29] K. Shigemasa,et al. Cloning of tumor-associated differentially expressed gene-14, a novel serine protease overexpressed by ovarian carcinoma. , 1999, Cancer research.
[30] W. Stetler-Stevenson,et al. Matrix metalloproteinases and metastasis , 1999, Cancer Chemotherapy and Pharmacology.
[31] E. Diamandis,et al. Prostate-specific Antigen: Its Usefulness in Clinical Medicine , 1998, Trends in Endocrinology & Metabolism.
[32] A. Partin,et al. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. , 1998, Critical reviews in clinical laboratory sciences.
[33] Y. Miyagi,et al. Differential expression of trypsin in human ovarian carcinomas and low-malignant-potential tumors. , 1998, Gynecologic oncology.
[34] L. Liotta,et al. General mechanisms of metastasis , 1997, Cancer.
[35] M. van Glabbeke,et al. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] K. Shigemasa,et al. Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. , 1997, Cancer research.
[37] H E Lambert,et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] A. Gadducci,et al. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses. , 1996, Gynecologic oncology.
[39] R. Bast,et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers , 1995, Cancer.
[40] M R Conaway,et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. , 1995, Gynecologic oncology.
[41] P. Sevelda,et al. Preoperative CA 125: An Independent Prognostic Factor in Patients With Stage I Epithelial Ovarian Cancer , 1995, Obstetrics and gynecology.
[42] J. Grudzinskas,et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography , 1994 .
[43] R. Bast,et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. , 1993, Journal of the National Cancer Institute.
[44] L. Liotta,et al. Molecular aspects of tumor cell invasion and metastasis , 1993, Cancer.
[45] R. Bast,et al. Prospective Evaluation of Serum CA 125 Levels for Early Detection of Ovarian Cancer , 1992, Obstetrics and gynecology.
[46] J. Stilwell,et al. Savings obtained by CA-125 measurements during therapy for ovarian carcinoma. The North Thames Ovary Group. , 1992, European journal of cancer.
[47] D. Oram,et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer , 1991, British journal of obstetrics and gynaecology.
[48] R. Bast,et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. , 1983, The New England journal of medicine.
[49] R. Bast,et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. , 1981, The Journal of clinical investigation.